Stockreport

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

FibroGen, Inc  (FGEN) 
Last fibrogen, inc earnings: 3/2 04:01 pm Check Earnings Report
PDF FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibi [Read more]